{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:36:12Z","timestamp":1792190172376,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T00:00:00Z","timestamp":1491264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T00:00:00Z","timestamp":1491264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is characterized in the majority of cases by a t(9;22)(q34;q11) translocation, also called the Philadelphia chromosome, giving rise to the BCR-ABL1 fusion protein. Current treatment with tyrosine kinase inhibitors is directed against the constitutively active ABL1 domain of the fusion protein, and minimal residual disease (MRD) after therapy is monitored by real-time quantitative PCR (RQ-PCR) of the fusion transcript. Here, we describe a novel approach to detect and enumerate cells positive for the BCR-ABL1 fusion protein by combining the <jats:italic>in situ<\/jats:italic> proximity ligation assay with flow cytometry as readout (PLA-flow). By targeting of the BCR and ABL1 parts of the fusion protein with one antibody each, and creating strong fluorescent signals through rolling circle amplification, PLA-flow allowed sensitive detection of cells positive for the BCR-ABL1 fusion at frequencies as low as one in 10,000. Importantly, the flow cytometric results correlated strongly to those of RQ-PCR, both in diagnostic testing and for MRD measurements over time. In summary, we believe this flow cytometry-based method can serve as an attractive approach for routine measurement of cells harboring BCR-ABL1 fusions, also allowing simultaneously assessment of other cell surface markers as well as sensitive longitudinal follow-up.<\/jats:p>","DOI":"10.1038\/s41598-017-00755-y","type":"journal-article","created":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T11:03:37Z","timestamp":1490785417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia"],"prefix":"10.1038","volume":"7","author":[{"given":"Liza","family":"L\u00f6f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Arng\u00e5rden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Siart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-9875","authenticated-orcid":false,"given":"Joakim S.","family":"Dahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Th\u00f6rn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christiansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Hermansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Ahlstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"W\u00e5linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2883-1925","authenticated-orcid":false,"given":"Ola","family":"S\u00f6derberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rosenquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7820-1000","authenticated-orcid":false,"given":"Ulf","family":"Landegren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood","family":"Kamali-Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,4]]},"reference":[{"key":"755_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen, J. et al. Philadelphia Chromosomal Breakpoints Are Clustured within a limited region, bcr, on chromosome 22. Cell \n                           36, 93\u201399, doi:10.1016\/0092-8674(84)90077-1 (1984).","journal-title":"Cell"},{"key":"755_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/306277a0","volume":"306","author":"CR Bartram","year":"1983","unstructured":"Bartram, C. R., d. K, A., Hagemeijer, A., van Agthoven, T., Geurts van Kessel, A. & Bootsma, D. et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature \n                           306, 277\u2013280, doi:10.1038\/306277a0 (1983).","journal-title":"Nature"},{"key":"755_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A de Klein","year":"1982","unstructured":"de Klein, A. et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature \n                           300, 765\u2013767, doi:10.1038\/300765a0 (1982).","journal-title":"Nature"},{"key":"755_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah, Y., Daley, G., Mes-Masson, A., Witte, O. & Baltimore, D. The chronic myelogenous leukemia-Specific P210 protein Is the product of the bcr\/abl Hybrid Gene. Science \n                           233, 212\u2013214, doi:10.1126\/science.3460176 (1986).","journal-title":"Science"},{"key":"755_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"J Rowley","year":"1973","unstructured":"Rowley, J. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identifed by quinacrine fluorescence and giemsa staining. Nature \n                           243, 290\u2013293, doi:10.1038\/243290a0 (1973).","journal-title":"Nature"},{"key":"755_CR6","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1056\/NEJM198810133191506","volume":"319","author":"R Kurzrock","year":"1988","unstructured":"Kurzrock, R., Gutterman, J. & Talpaz, M. The molecular genetics of Philadelphia chromosome-positive leukemias. New England Journal of Medicine \n                           319, 990\u2013998, doi:10.1056\/NEJM198810133191506 (1988).","journal-title":"New England Journal of Medicine"},{"key":"755_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.leu.2402329","volume":"16","author":"C Schoch","year":"2002","unstructured":"Schoch, C. et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia \n                           16, 53\u201359, doi:10.1038\/sj.leu.2402329 (2002).","journal-title":"Leukemia"},{"key":"755_CR8","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","volume":"13","author":"J van Dongen","year":"1999","unstructured":"van Dongen, J. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia \n                           13, 1901\u20131928, doi:10.1038\/sj.leu.2401592 (1999).","journal-title":"Leukemia"},{"key":"755_CR9","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1073\/pnas.85.15.5698","volume":"85","author":"ES Kawasaki","year":"1988","unstructured":"Kawasaki, E. S. et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proceedings of the National Academy of Sciences of the United States of America \n                           85, 5698\u20135702, doi:10.1073\/pnas.85.15.5698 (1988).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"755_CR10","doi-asserted-by":"crossref","unstructured":"Fainstein, E. et al. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature (1987).","DOI":"10.1038\/330386a0"},{"key":"755_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1046\/j.1365-2141.1998.01033.x","volume":"103","author":"BD Lichty","year":"1998","unstructured":"Lichty, B. D. et al. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. Brit J Haematol \n                           103, 711\u2013715, doi:10.1046\/j.1365-2141.1998.01033.x (1998).","journal-title":"Brit J Haematol"},{"key":"755_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0065-230X(08)60796-4","volume":"49","author":"WH Raskind","year":"1987","unstructured":"Raskind, W. H. & Fialkow, P. J. The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res \n                           49, 127\u2013167, doi:10.1016\/S0065-230X(08)60796-4 (1987).","journal-title":"Adv Cancer Res"},{"key":"755_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0065-230X(08)60796-4","volume":"49","author":"FP Raskind W. H.","year":"1987","unstructured":"Raskind W. H., F. P. The use of cell markers in the study of human hemopoietic neoplasia. Adv Cancer Res \n                           49, 127\u2013132, doi:10.1016\/S0065-230X(08)60796-4 (1987).","journal-title":"Adv Cancer Res"},{"key":"755_CR14","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. The Lancet. Oncology \n                           11, 1029\u20131035, doi:10.1016\/S1470-2045(10)70233-3 (2010).","journal-title":"The Lancet. Oncology"},{"key":"755_CR15","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood-2012-02-408229","volume":"120","author":"L Legros","year":"2012","unstructured":"Legros, L. et al. Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. Blood \n                           120, 1959\u20131960, doi:10.1182\/blood-2012-02-408229 (2012).","journal-title":"Blood"},{"key":"755_CR16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet, D. & Dick, J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine \n                           3, 730\u2013737, doi:10.1038\/nm0797-730 (1997).","journal-title":"Nature Medicine"},{"key":"755_CR17","doi-asserted-by":"crossref","unstructured":"Stuart, S. A., Minami., Y., - Wang, J. Y. J. & Wang, J. Y. The CML stem cell: evolution of the progenitor. Cell Cycle (2009).","DOI":"10.4161\/cc.8.9.8209"},{"key":"755_CR18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/nmeth947","volume":"3","author":"O Soderberg","year":"2006","unstructured":"Soderberg, O. et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nature methods \n                           3, 995\u20131000, doi:10.1038\/nmeth947 (2006).","journal-title":"Nature methods"},{"key":"755_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/cyto.a.20771","volume":"75A","author":"KJ Leuchowius","year":"2009","unstructured":"Leuchowius, K. J., Weibrecht, I., Landegren, U., Gedda, L. & Soderberg, O. Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family. Cytom Part A \n                           75A, 833\u2013839, doi:10.1002\/cyto.a.v75a:10 (2009).","journal-title":"Cytom Part A"},{"key":"755_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/cncr.29142","volume":"121","author":"F El Rassi","year":"2015","unstructured":"El Rassi, F. et al. Predicting early blast transformation in chronic-phase chronic myeloid leukemia: Is immunophenotyping the missing link? Cancer \n                           121, 872\u2013875, doi:10.1002\/cncr.v121.6 (2015).","journal-title":"Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00755-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T03:26:28Z","timestamp":1671765988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00755-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,4]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-00755-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,4]]},"assertion":[{"value":"23 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UL is founder and holds stock in Olink Bioscience, having rights to the <i>in situ<\/i> PLA technique.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"623"}}